Hympavzi (Marstacimab)

Marstacimab is a monoclonal antibody that binds to tissue factor pathway inhibitor (TFPI). This binding neutralises TFPI, allowing the extrinsic coagulation cascade to proceed unchecked, which increases factor Xa and thrombin generation. The resulting boost in thrombin compensates for the missing clotting factors in hemophilia.

The dose of Hympavzi is determined by the prescribing healthcare professional based on the patient’s weight, severity of hemophilia, and clinical response. Specific dosing regimens are not publicly disclosed and should be obtained from the treating physician or specialist.

Safety data for Hympavzi in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Hympavzi product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Hympavzi differs from factor replacement therapies and bispecific antibodies such as emicizumab. While factor concentrates replace the missing clotting factor directly, Hympavzi enhances the body’s own thrombin generation by blocking TFPI. This mechanism can provide a broader hemostatic effect and may be useful in patients with inhibitors to factor VIII or IX.

Hympavzi must be stored in a refrigerator at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. If temperature excursions occur, the product should be inspected for visual changes before use.

Hympavzi is given by subcutaneous injection. The injection is typically performed by a trained healthcare professional in a clinical setting, following aseptic technique. The exact injection site and frequency are determined by the prescribing clinician.

The most serious risks include thrombotic events such as arterial or venous clots, severe hypersensitivity reactions including anaphylaxis, and the possible development of neutralising antibodies that could reduce efficacy. Patients should be monitored closely for any signs of these events.

Hympavzi should not be used in individuals with known hypersensitivity to Marstacimab or any of its excipients, in patients with active thrombotic disease, or in those where the risk of thrombosis outweighs the benefit. Contra‑indications are determined by the treating physician.